105 related articles for article (PubMed ID: 8409700)
1. Anthracycline toxicity is potentiated by iron and inhibited by deferoxamine: studies in rat heart cells in culture.
Hershko C; Link G; Tzahor M; Kaltwasser JP; Athias P; Grynberg A; Pinson A
J Lab Clin Med; 1993 Sep; 122(3):245-51. PubMed ID: 8409700
[TBL] [Abstract][Full Text] [Related]
2. Effect of iron loading on transmembrane potential, contraction, and automaticity of rat ventricular muscle cells in culture.
Link G; Athias P; Grynberg A; Pinson A; Hershko C
J Lab Clin Med; 1989 Jan; 113(1):103-11. PubMed ID: 2909644
[TBL] [Abstract][Full Text] [Related]
3. Role of iron in the potentiation of anthracycline cardiotoxicity: identification of heart cell mitochondria as a major site of iron-anthracycline interaction.
Link G; Tirosh R; Pinson A; Hershko C
J Lab Clin Med; 1996 Mar; 127(3):272-8. PubMed ID: 9273360
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy.
Martin E; Thougaard AV; Grauslund M; Jensen PB; Bjorkling F; Hasinoff BB; Tjørnelund J; Sehested M; Jensen LH
Toxicology; 2009 Jan; 255(1-2):72-9. PubMed ID: 19010377
[TBL] [Abstract][Full Text] [Related]
5. Nitric oxide and oxidative stress in brain and heart of normal rats treated with doxorubicin: role of aminoguanidine.
Abd El-Gawad HM; El-Sawalhi MM
J Biochem Mol Toxicol; 2004; 18(2):69-77. PubMed ID: 15122648
[TBL] [Abstract][Full Text] [Related]
6. Desferal inhibits breast tumor growth and does not interfere with the tumoricidal activity of doxorubicin.
Hoke EM; Maylock CA; Shacter E
Free Radic Biol Med; 2005 Aug; 39(3):403-11. PubMed ID: 15993339
[TBL] [Abstract][Full Text] [Related]
7. Heart cells in culture: a model of myocardial iron overload and chelation.
Link G; Pinson A; Hershko C
J Lab Clin Med; 1985 Aug; 106(2):147-53. PubMed ID: 4020242
[TBL] [Abstract][Full Text] [Related]
8. Prevention of chronic anthracycline cardiotoxicity in the adult Fischer 344 rat by dexrazoxane and effects on iron metabolism.
Cusack BJ; Gambliel H; Musser B; Hadjokas N; Shadle SE; Charlier H; Olson RD
Cancer Chemother Pharmacol; 2006 Oct; 58(4):517-26. PubMed ID: 16555089
[TBL] [Abstract][Full Text] [Related]
9. Protective effect of aminoguanidine against cardiovascular toxicity of chronic doxorubicin treatment in rats.
Mostafa AM; Nagi MN; Al Rikabi AC; Al-Shabanah OA; El-Kashef HA
Res Commun Mol Pathol Pharmacol; 1999; 106(3):193-202. PubMed ID: 11485049
[TBL] [Abstract][Full Text] [Related]
10. Amelioration of adriamycin and daunorubicin myocardial toxicity by adenosine.
Newman RA; Hacker MP; Krakoff IH
Cancer Res; 1981 Sep; 41(9 Pt 1):3483-8. PubMed ID: 7260911
[TBL] [Abstract][Full Text] [Related]
11. Changes in gene expression with iron loading and chelation in cardiac myocytes and non-myocytic fibroblasts.
Parkes JG; Liu Y; Sirna JB; Templeton DM
J Mol Cell Cardiol; 2000 Feb; 32(2):233-46. PubMed ID: 10722800
[TBL] [Abstract][Full Text] [Related]
12. Iron is not involved in oxidative stress-mediated cytotoxicity of doxorubicin and bleomycin.
Kaiserová H; den Hartog GJ; Simůnek T; Schröterová L; Kvasnicková E; Bast A
Br J Pharmacol; 2006 Dec; 149(7):920-30. PubMed ID: 17031387
[TBL] [Abstract][Full Text] [Related]
13. Cell-permeable superoxide dismutase and glutathione peroxidase mimetics afford superior protection against doxorubicin-induced cardiotoxicity: the role of reactive oxygen and nitrogen intermediates.
Konorev EA; Kennedy MC; Kalyanaraman B
Arch Biochem Biophys; 1999 Aug; 368(2):421-8. PubMed ID: 10441396
[TBL] [Abstract][Full Text] [Related]
14. Anthracycline-induced cardiac injury using a cardiac cell line: potential for gene therapy studies.
L'Ecuyer T; Horenstein MS; Thomas R; Vander Heide R
Mol Genet Metab; 2001 Nov; 74(3):370-9. PubMed ID: 11708868
[TBL] [Abstract][Full Text] [Related]
15. Doxorubicin irreversibly inactivates iron regulatory proteins 1 and 2 in cardiomyocytes: evidence for distinct metabolic pathways and implications for iron-mediated cardiotoxicity of antitumor therapy.
Minotti G; Ronchi R; Salvatorelli E; Menna P; Cairo G
Cancer Res; 2001 Dec; 61(23):8422-8. PubMed ID: 11731422
[TBL] [Abstract][Full Text] [Related]
16. Deferoxamine-induced iron mobilization and redistribution of myocardial iron in cultured rat heart cells: studies of the chelatable iron pool by electron microscopy and Mössbauer spectroscopy.
Shiloh H; Iancu TC; Bauminger ER; Link G; Pinson A; Hershko C
J Lab Clin Med; 1992 Apr; 119(4):428-36. PubMed ID: 1583395
[TBL] [Abstract][Full Text] [Related]
17. Effects of pyrroline and pyrrolidine nitroxides on lipid peroxidation in heart tissue of rats treated with doxorubicin.
Koceva-Chyła A; Gwoździński K; Kochman A; Stolarska A; Jóźwiak Z
Cell Mol Biol Lett; 2003; 8(1):179-83. PubMed ID: 12655372
[TBL] [Abstract][Full Text] [Related]
18. Cardiotoxicity of doxorubicin/paclitaxel combination in rats: effect of sequence and timing of administration.
Saad SY; Najjar TA; Alashari M
J Biochem Mol Toxicol; 2004; 18(2):78-86. PubMed ID: 15122649
[TBL] [Abstract][Full Text] [Related]
19. Iron chelation by clinically relevant anthracyclines: alteration in expression of iron-regulated genes and atypical changes in intracellular iron distribution and trafficking.
Xu X; Sutak R; Richardson DR
Mol Pharmacol; 2008 Mar; 73(3):833-44. PubMed ID: 18029550
[TBL] [Abstract][Full Text] [Related]
20. The role of iron and iron chelators in anthracycline cardiotoxicity.
Hershko C; Link G; Tzahor M; Pinson A
Leuk Lymphoma; 1993 Oct; 11(3-4):207-14. PubMed ID: 8260895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
